home / stock / labp / labp news

LABP News and Press, Landos Biopharma Inc. From 09/01/21

Stock Information
Company Name: Landos Biopharma Inc.
Stock Symbol: LABP
Market: NASDAQ
Website: landosbiopharma.com
Menu
LABP LABP Quote LABP Short LABP News LABP Articles LABP Message Board
Get LABP Alerts

News, Short Squeeze, Breakout and More Instantly...
LABP - Landos Biopharma to Participate in Two Upcoming Investor Conferences in September

BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE ® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Jos...
LABP - Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine

BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE ® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that it h...

LABP - Landos Biopharma to Participate in Upcoming Investor Events

BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE ® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Jose...

LABP - Seeking Alpha Catalyst Watch

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
LABP - Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates

Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated global pivotal Phase 3 clinical trial site feasibility studies of omilancor in ulcerative colitis (UC) Initiated enrollment of Phase 2 trial of omilancor in Crohn’s Disease (CD); t...

LABP - Landos Biopharma's Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021

Omilancor shows efficacy and tolerability as a potential once-daily, oral, gut-restricted therapy for mild-to-moderate UC patients Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated clinical trial site feasibility studies for the planned global p...

LABP - Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Jo...
LABP - Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting

Landos Biopharma (LABP) announces the successful outcome of an End-of-Phase 2 ((EOP2)) meeting with the U.S. FDA for omilancor, its lead candidate in late-stage clinical development for the treatment of mild-to-moderate active ulcerative colitis ((UC)) patients.Landos and the FDA agreed on ke...

LABP - Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced Artificial Intelligence (A.I.) platform to discover and develop novel oral therapeutics for patients with autoimmune and inf...

LABP - Landos Biopharma (LABP) Investor Presentation - Slideshow

The following slide deck was published by Landos Biopharma, Inc. in conjunction with this event. For further details see: Landos Biopharma (LABP) Investor Presentation - Slideshow

Previous 10 Next 10